WBC100

• CAT Number: I041194
• CAS Number: 2095780-08-6
• Molecular Formula: C25H33NO7
• Molecular Weight: 459.53
• Purity: ≥95%
• Synonyms: [(1S,2S,4S,5S,7S,8R,9R,11S,13S)-1-methyl-17-oxo-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-8-yl] (2R)-2-amino-3-methylbutanoate
• InChI: InChI=1S/C25H33NO7/c1-10(2)16(26)20(28)30-21-23(11(3)4)17(32-23)18-25(33-18)22(5)7-6-12-13(9-29-19(12)27)14(22)8-15-24(21,25)31-15/h10-11,14-18,21H,6-9,26H2,1-5H3/t14-,15-,16+,17-,18-,21+,22-,23-,24+,25+/m0/s1
• InChIKey: OWLJDBBFRJXPGM-VBIGTWTASA-N
• SMILES: CC(C)[C@H](C(=O)O[C@H]1[C@@]23[C@@H](O2)C[C@H]4C5=C(CC[C@@]4([C@]36[C@@H](O6)[C@H]7[C@@]1(O7)C(C)C)C)C(=O)OC5)N

WBC100（Cat No.:I041194）is an investigational small molecule being developed for its potential use in treating autoimmune diseases and cancer. It works by modulating immune cell activity, specifically targeting pathways involved in inflammation and immune responses. WBC100 has shown promise in preclinical studies for reducing excessive immune activation and suppressing tumor growth in cancer models. Its mechanism of action involves regulating immune cell trafficking and cytokine production, which are key factors in the development of autoimmune disorders and cancer. Ongoing clinical trials are evaluating its safety, efficacy, and potential therapeutic benefits in these areas.